XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Ophthalmic drug products are sterile, but they are not parenterals. The endotoxin limits that govern every injectable drug product do not apply to topical ophthalmic products.
View details →
The FDA product-specific guidance for your MDI reference listed drug tells you the exact cascade impactor, the exact flow rate, the exact stage mass acceptance criteria, and the exact number of actuations to collect
View details → A nasal spray ANDA does not need in vivo pharmacokinetic bioequivalence. The drug that deposits in the nasal mucosa acts locally, and the systemic PK curve doesn't reflect where the drug is or what
View details →
A PFS needle shield change sounds like a device engineering decision. It is a regulatory submission decision.
View details →
Most pharmaceutical technology transfers are managed as project milestones — equipment qualification, training records, validation batches, and a final summary report. What FDA inspectors evaluate at a pre-approval inspection is something different: they look
View details →
GMP compliance and manufacturing capability are not the same thing. A CMO can pass a GMP audit — clean facilities, validated equipment, current SOPs, trained personnel, compliant batch records — and still be technically
View details → Drug substance technology transfers fail most visibly when the commercial manufacturing site produces an impurity that the development site never made. This happens more often than process chemists anticipate — different raw material suppliers,
View details → A drug product batch that meets all release specifications at commercial scale is not the same as a drug product that has demonstrated process equivalence to the clinical manufacturing batches. Specification compliance means the
View details → Analytical method transfer programs that use specification compliance as the transfer acceptance criterion are measuring the wrong thing. If the drug product assay specification is 95–105% of label claim, and the sending site consistently
View details → When you transfer your manufacturing process into a multi-product CMO, cleaning validation stops being the CMO's general housekeeping practice and becomes a regulatory control specific to your API. The question FDA investigators ask during
View details → Selecting a CMO and signing the manufacturing agreement is not the beginning of the regulatory pathway to an approved manufacturing site — it is the business step that precedes the regulatory program. The regulatory
View details → The CMO technical agreement is the last place most CMC teams look when a manufacturing crisis hits — and the first place they should have looked when the agreement was being negotiated. When a
View details → Supply chain redundancy is the supply chain strategy. Dual-source manufacturing is the regulatory program that makes supply chain redundancy work. The difference matters because the second source cannot supply commercial product until it is
View details → An FDA-approved NDA is not a J-NDA CMC package. The ICH CTD format is common. The regulatory expectations are not.
View details → Health Canada operates under the same ICH CTD framework and uses the same ICH guideline set as FDA. None of that means a Health Canada CTA CMC package is the same as an FDA
View details → The ICH CTD format harmonized the structure of global drug regulatory submissions. It did not harmonize what goes inside them.
View details → The EMA CHMP centralized procedure has a 210-day review clock, but it has never taken 210 days for an applicant to discover what a Major Objection on quality looks like.
View details → ICH Q8, Q9, and Q10 represent the most successful pharmaceutical regulatory harmonization initiative in history — and also one of the most consistently misunderstood.
View details →